Anemia
Feature
EHA and TIF explore how COVID-19 is affecting thalassemia and SCD patients
Feature
Pandemic strains blood supply for COVID-19 and noninfected patients
From the Journals
Severe COVID-19 may lower hemoglobin levels
...
Feature
ASH tackles COVID-19 with hematology-related FAQ, promotes new registries
From the Journals
Low plasma sodium levels can predict complications in acute painful episodes of SCD
Conference Coverage
Deferiprone noninferior to deferoxamine for iron overload in SCD, rare anemias
An oral iron chelator granted accelerated approval for thalassemia is noninferior to deferoxamine for iron overload in patients with sickle cell...
Conference Coverage
BCL11A-directed gene therapy advances in sickle cell disease
ORLANDO – A phase 2/3 study is planned to assess the gene therapy in a larger group of patients with sickle cell disease.
Conference Coverage
ASH releases guidelines on managing cardiopulmonary and kidney disease in SCD
ORLANDO – ASH has released the first of five new sets of sickle cell disease guidelines, with the first focusing on screening and management of...
Conference Coverage
Sutimlimab boosts hemoglobin, quality of life in cold agglutinin disease
ORLANDO – A novel antibody targeted to the complement pathway increased hemoglobin and improved quality of life in patients with cold agglutinin...
Conference Coverage
NFIX could be a target for sickle cell therapy
ORLANDO – Preclinical research suggests it may be a fetal hemoglobin repressor.
News from the FDA/CDC
FDA approves Oxbryta for sickle cell disease treatment
The drug, which is approved for adults and children aged 12 years and older, improved hemoglobin in the HOPE trial.